RESEARCH PAPER
Acute adverse-effect profi le of ethosuximide and stiripentol in the grip-strength test in mice
1
Department of Pathophysiology, Medical University, Lublin, Poland; Department of Physiopathology, Institute of Agricultural Medicine, Lublin, Poland
Corresponding author
Jarogniew J. Łuszczki
Department of Pathophysiology, Medical University, Jaczewskiego 8, 20-090 Lublin, Poland.
Department of Pathophysiology, Medical University, Jaczewskiego 8, 20-090 Lublin, Poland.
J Pre Clin Clin Res. 2009;3(1):45–48
KEYWORDS
ABSTRACT
The aim of the study was assessment of acute adverse (neurotoxic) effects of ethosuximide and stiripentol (two antiepileptic drugs) in the grip-strength test by measuring skeletal muscular strength in mice. Linear regression analysis of dose-response relationship for drug doses and their corresponding skeletal muscular strength allowed determination of the doses of antiepileptic drugs that reduced the grip-strength in mice by 50%, compared with control animals. Results indicate that the experimentally-derived dose reducing muscular strength in mice by 50% (D50) for ethosuximide was 755.4 mg/kg and that for stiripentol was 971.2 mg/kg. The studied antiepileptic drugs reduced skeletal muscular strength in mice in a dose-dependent manner.
REFERENCES (26)
1.
MJ: Combination therapy in epilepsy: when and what to use. Drugs 2006, 66, 1817-1829.
2.
Kwan P, Brodie MJ: Refractory epilepsy: a progressive, intractable but preventable condition? Seizure 2002, 11, 77-84.
3.
Brodie MJ, Schachter SC: Fast Facts. Epilepsy, 2nd edn., Health Press, Oxford, 2001.
4.
Deckers CL, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, Patsalos PN, Renier WO, Van Rijn CM: Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000, 41, 1364-1374.
5.
Perucca E, Kwan P: Overtreatment in epilepsy: how it occurs and how it can be avoided. CNS Drugs 2005, 19, 897-908.
6.
Perucca E: Pharmacological principles as a basis for polytherapy. Acta Neurol Scand Suppl 1995, 162, 31-34.
7.
Schmidt D: Strategies to prevent overtreatment with antiepileptic drugs in patients with epilepsy. Epilepsy Res 2002, 52, 61-69.
8.
Loscher W, Nolting B: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices. Epilepsy Res 1991, 9, 1-10.
9.
Łuszczki JJ, Zadrożniak A, Wlaź A, Andres-Mach M, Dudra-Jastrzębska M, Zwoliński J, Misiuta-Krzesińska M, Sielski M: Characterization of acute adverse-eff ect profi le of carbamazepine and valproate in the grip-strength test in mice. J Pre-Clin Clin Res 2008, 2, 46-48.
10.
Zadrożniak A, Wojda E, Wlaź A, Łuszczki JJ: Characterization of acute adverse-eff ect profi le of some selected antiepileptic drugs in the grip-strength test in mice. Pharmacol Rep 2009, 61, In press.
11.
Motulsky HJ, Christopoulos A: Fitting models to biological data using linear and nonlinear regression. A practical guide to curve fi tting. GraphPad Software Inc., San Diego CA, 2003.
12.
Łuszczki JJ, Andres MM, Czuczwar P, Cioczek-Czuczwar A, WojcikĆwikła J, Ratnaraj N, Patsalos PN, Czuczwar SJ: Levetiracetam selectively potentiates the acute neurotoxic eff ects of topiramate and carbamazepine in the rotarod test in mice. Eur Neuropsychopharmacol 2005, 15, 609-616.
13.
Łuszczki JJ, Andres MM, Czuczwar P, Cioczek-Czuczwar A, WojcikĆwikła J, Ratnaraj N, Patsalos PN, Czuczwar SJ: Levetiracetam selectively potentiates the acute neurotoxic eff ects of topiramate and carbamazepine in the rotarod test in mice. Eur Neuropsychopharmacol 2005, 15, 609-617.
14.
Łuszczki JJ, Czuczwar M, Kiś J, Krysa J, Pasztelan I, Świąder M, Czuczwar SJ: Interactions of lamotrigine with topiramate and fi rstgeneration antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003, 44, 1003-1013.
15.
Meyer OA, Tilson HA, Byrd WC, Riley MT: A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav Toxicol 1979, 1, 233-236.
16.
Łuszczki JJ, Czuczwar SJ: Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31, 529- 538.
17.
Coulter DA, Huguenard JR, Prince DA: Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol 1998, 25, 582-593.
18.
Gomora JC, Daud AN, Weiergraber M, Perez-Reyes E: Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol 2001, 60, 1121-1132.
19.
Leresche N, Parri HR, Erdemli G, Guyon A, Turner JP, Williams SR, Asprodini E, Crunelli V: On the action of the antiabsence drug ethosuximide in the rat and cat thalamus. J Neurosci 1998, 18, 4842- 4853.
20.
Crunelli V, Leresche N: Block of thalamic T-type Ca2+ channels by ethosuximide is not the whole story. Epilepsy Curr 2002, 2, 53-56.
21.
Kobayashi T, Hirai H, Iino M, Fuse I, Mitsumura K, Washiyama K, Kasai S, Ikeda K: Inhibitory eff ects of the antiepileptic drug ethosuximide on G protein-activated inwardly rectifying K+ channels. Neuropharmacology 2009, 56, 499-506.
22.
Poisson M, Huguet F, Savattier A, Bakri-Logeais F, Narcisse G: A new type of anticonvulsant, stiripentol. Pharmacological profi le and neurochemical study. Arzneimittelforschung 1984, 34, 199-204.
23.
Wegmann R, Ilies A, Aurousseau M: Pharmaco-cellular enzymology of the mechanism of action of stiripentol in cardiazol-induced epilepsy. III. Protein, nucleoprotein, lipid, and proteoglycan metabolism. Cell Mol Biol Incl Cyto-Enzymol 1978, 23, 455-480.
24.
Quilichini PP, Chiron C, Ben-Ari Y, Gozlan H: Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA receptor channels. Epilepsia 2006, 47, 704-716.
25.
Shen DD, Levy RH, Savitch JL, Boddy AV, Tombret F, Lepage F: Comparative anticonvulsant potency and pharmacokinetics of (+)- and (-)-enantiomers of stiripentol. Epilepsy Res 1992, 12, 29-36.
26.
Than M, Kocsis P, Tihanyi K, Fodor L, Farkas B, Kovacs G, Kis-Varga A, Szombathelyi Z, Tarnawa I: Concerted action of antiepileptic and antidepressant agents to depress spinal neurotransmission: Possible use in the therapy of spasticity and chronic pain. Neurochem Int 2007, 50, 642-652.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.